Cargando…
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is derived mostly from a background of chronic inflammation. Multiple immunotherapeutic strategies have been evaluated in HCC, with some degree of success, particularly with immune checkpoint blockade (ICB). Despite the initial en...
Autores principales: | Tai, David, Choo, Su Pin, Chew, Valerie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966558/ https://www.ncbi.nlm.nih.gov/pubmed/31816940 http://dx.doi.org/10.3390/cancers11121926 |
Ejemplares similares
-
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020) -
Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective
por: Chen, Shuling, et al.
Publicado: (2022) -
Targeted Therapy in Hepatocellular Carcinoma
por: Chua, Clarinda W. L., et al.
Publicado: (2011) -
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
por: Ao, Huang, et al.
Publicado: (2021) -
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
por: Mitsis, Demytra, et al.
Publicado: (2016)